Estudo bioquímico e reprodutivo em ratas wistar prenhes imunossuprimidas pela ciclosporina A

Abstract

Pregnancy is characterized by complex and intense adaptive physiological changes necessary for the biological stability for preservation of maternal and fetal health. During pregnancy a woman may have the need to use drugs, whether for reasons of pre-existing disease or current pathological condition. However, the use of drugs are able to cross the placenta and reach the fetus as well, which implies a potential risk for the same. Among the drugs that cross the placental barrier are immunosuppressive agents which are used for post-transplant women and in those autoimmune diseases. The objective of this study was to evaluate the effects of immunosuppressive therapy with Cyclosporine A in reproductive profile and biochemical in pregnant Wistar rats. The rats were randomized into three groups CONT (treated with tap water), CLP1 (treated with Cyclosporin A 15 mg / kg before and during pregnancy) and CLP2 (treated with Cyclosporin A 15 mg / kg before pregnancy). The body weight, food and water intake, and glucose were measured weekly. On the 17th day of pregnancy it was evaluated the oral glucose tolerance test (OGTT). The reproductive parameters were determined by fertility indices, pregnancy and childbirth. On the last day of pregnancy (day 21), serum biochemical analysis were performed (total protein, cholesterol, triglycerides from high density lipoprotein (HDL) cholesterol and very low density lipoprotein (VLDL). TNF-α levels were determined serum and placental by enzyme immunoassay. The statistical significance was considered p<0.05. It was observed a progressive increase in body weight during the pregnancy in all groups compared to the first day. In addition, the continued use of this drug decreased food intake and slightly blood glucose. the reproductive parameters have not changed. The glycemic curve generated by OGTT show the timepoint of 120 minutes of CLP1 group was increased related to other groups. In biochemical evaluation, TNF-α levels, cholesterol and HDL were unchanged, but the treatment with the drug led increase in protein concentration (CLP2), triglyceride and VLDL (CLP1) and also an increase in ALT activity, AST and reduced (in both groups). We can conclude that the use of Cyclosporine A prior and/or during pregnancy has some security for weight gain, lipid metabolism and also maternal insulin action in maternal organism.